Experimental and clinical trial investigations of phyto-extracts, phyto-chemicals and phyto-formulations against oral lichen planus: A systematic review

Sahoo, Alaka; Jena, Ashok Kumar; Panda, Maitreyee

doi:10.1016/j.jep.2022.115591

Cited by 13 publications

(12 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indian Ayurveda and Traditional Chinese medicine regimens/herbal components demonstrated multipotential effects with fewer side effects. Therefore, these components could serve as a cost‐effective and alternative medicine after being tested experimentally and pharmacologically [8,9,43,46,47] . However, the transformation of ‘lead phytochemical’ to ‘mainstream drug’ is a complicated long‐term process and due to poor drug‐ability profiles, most active candidates fail in different phases of the clinical trial.…”

Section: Resultsmentioning

confidence: 99%

“…Therefore, these components could serve as a cost-effective and alternative medicine after being tested experimentally and pharmacologically. [8,9,43,46,47] However, the transformation of 'lead phytochemical' to 'mainstream drug' is a complicated long-term process and due to poor drug-ability profiles, most active candidates fail in different phases of the clinical trial. In a naturalproduct based drug discovery module, therefore, proper expertise, screening procedures and strategies are essential.…”

Section: Structural Activity Relationship Analysismentioning

confidence: 99%

See 1 more Smart Citation

Combined Bioinformatics and Combinatorial Chemistry Tools to Locate Drug‐Able Anti‐TB Phytochemicals: A Cost‐Effective Platform for Natural Product‐Based Drug Discovery

Swain

Hussain

2022

Chemistry & Biodiversity

View full text Add to dashboard Cite

Based on extensive experimental studies, a huge number of phytochemicals showed potential activity against tuberculosis (TB) at a lower minimum inhibitory concentration (MIC) and fewer toxicity profiles. However, these promising drugs have not been able to convert from 'lead' to 'mainstream' due to inadequate drug-ability profiles. Thus, early drug-prospective analyses are required at the primary stage to accelerate natural-productbased drug discovery with limited resources and time. In the present study, we have selected seventy-three potential anti-TB phytochemicals (MIC value � 10 μg/mL) and assessed the drug-ability profiles using bioinformatics and combinatorial chemistry tools, systematically. Primarily, the molecular docking study was done against two putative drug targets, catalase-peroxidase enzyme (katG) and RNA polymerase subunit-β (rpoB) of Mycobacterium tuberculosis (Mtb) using AutoDock 4.2 software. Further, assessed the drug-ability score from Molsoft, toxicity profiles from ProTox, pharmacokinetics from SwisADME, hierarchical cluster analysis (HCA) by ChemMine tools and frontier molecular orbitals (FMOs) with Avogadro and structural activity relationships (SAR) analysis with ChemDraw 18.0 software. Above analyses indicated that, lower MIC exhibited anti-TB phytochemicals, abietane, 12-demethylmulticaulin exhibited poor docking and drug-ability scores, while tiliacorinine, 2-nortiliacorinine showed higher binding energy and drug-ability profiles. Overall, tiliacorinine, 2-nortiliacorinine, 7α-acetoxy-6β-hydroxyroyleanone (AHR), (2S)-naringenin and isovachhalcone were found as the most active and drug-able anti-TB candidates from 73 candidates. Phytochemicals are always a vital source of mainstream drugs, but the MIC value of a phytochemical is not sufficient for it to be promoted. An ideal drugability profile is therefore essential for achieving clinical success, where advanced bioinformatics tools help to assess and analyse that profile. Additionally, several natural pharmacophores found in existing anti-TB drugs in SAR analyses also provide crucial information for developing potential anti-TB drug. As a conclusion, combined bioinformatics and combinatorial chemistry are the most effective strategies to locate potent-cum-drug-able candidates in the current drug-development module.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Structural Activity Relationship Analysismentioning

confidence: 99%

Combined Bioinformatics and Combinatorial Chemistry Tools to Locate Drug‐Able Anti‐TB Phytochemicals: A Cost‐Effective Platform for Natural Product‐Based Drug Discovery

Swain

Hussain

2022

Chemistry & Biodiversity

View full text Add to dashboard Cite

show abstract

“…Estrogen and apremilast increased VEGF levels (21,28). Estrogen, angiogenesis, metastasis, and antiestrogen treatment all have an effect on breast cancer (26,27,29). More research is required on the hormonal regulation of angiogenic factors and angiogenesis in breast cancer (22)(23)(24).…”

Section: Discussionmentioning

confidence: 99%

Apremilast Treatment of Cancer in Mice Tumorised with Breast Cancer: In Vivo Study

2023

JPTCP

View full text Add to dashboard Cite

It is widely accepted that vascular endothelial growth factor, often abbreviated as VEGF, is an important mediator in the process of tumor angiogenesis, which includes neovascularization in human breast cancer. Patients with either node-positive or node-negative breast cancer have a worse prognosis overall if there are high levels of VEGF in the tissue. It would seem logical to expect a poor prognosis given these circumstances. There is evidence that the partial estrogen receptor agonist apremilast may increase the quantity of VEGF mRNA that is generated in breast cancer cells, suggesting that hormones may regulate the amount of VEGF that is expressed. However, the findings of clinical studies show that apremilast increases average survival rates while reducing the incidence of metastases. These results seem to raise questions about apremilast's efficacy as an adjuvant treatment for estrogen-dependent breast cancer. In this study, we demonstrate for the first time that apremilast can lower extracellular VEGF levels in vivo using solid MCF-7 tumors in naked mice. Nothing like to this has ever been done. Following the injection of apremilast, the levels of extracellular VEGF seen in the cell culture conditions were dramatically decreased. The in vivo outcomes that were found were supported by these findings.

show abstract

“…Active phytochemicals present in medicinal plants were reported to suppress the growth and advancement of tumors in diseased patients. 20 Further, different phytochemicals are responsible for the development of NPs, when plant extracts are used to manufacture NPs. Tracelevel attachments of these phytoconstituents to NPs are not ruled out.…”

Section: However They Are Generally Clustered Into Two Classes Namely...mentioning

confidence: 99%

Biogenic Zinc Oxide Nanoparticles Attenuate Acute Lymphoblastic Leukemia Cell Proliferation through Oxidative Stress and DNA Damage

Sujatha,

Venkatesan,

Sancharan

et al. 2024

Pharm Sci

View full text Add to dashboard Cite

Background: The most prevalent pediatric cancer is acute lymphoblastic leukemia (ALL). It is exceedingly challenging to treat recurrent diseases, and there aren’t many new medications available for children with disease resistance. The size-dependent anticancer effect of zinc oxide nanoparticles (ZnONPs) on T-cell acute lymphoblastic leukemia (T-ALL) cell line MOLT 3 is the central theme of this study. Methods: The leaf and bark extracts of Diospyros montana were subjected to nanoparticle (NPs) synthesis and characterized analytically to acquire ZnONPs. The ZnONPs were characterized using UV-Vis spectra, DLS, XRD, EDX, SEM, and TEM analysis. Then the ZnONPs were separated into two groups having <50 nm and 50-100 nm NPs sizes. In addition, MTT assay, dual staining, autophagy, DNA damage, and oxidative damage measurement were done to find out the anti-cancer effect of the ZnONPs on MOLT 3 cells. Results: The ZnONPs exhibited a size-dependent anticancer effect against MOLT 3 cells. The IC50 of ZnONPs of < 50 nm was found to be ~75 µg/mL while the IC50 of ZnONPs of 50-100 nm size was found to be ~102 µg/mL. Treatment with ZnONPs of <50 nm size decreased mitochondrial membrane potential, more than that with 50-100 nm ZnONPs. On the other hand, autophagy was found to be more prevalent in 50-100 nm treated ZnONPs when compared with < 50 nm size. However, treatment with both sizes of ZnONPs reduced cell proliferation markers such as ki67 positive cells while increasing 8-OHG and HDCF-DA positive cells. Conclusion: The obtained results portrayed that different-sized ZnONPs induce different modes of T-ALL cell death. Small-sized ZnONPs revealed higher efficacy, highlighting the size-dependent property. Further, this finding denotes that ZnONPs could be an effective anticancer agent against dreadful diseases like T-ALL, warranting further investigation.

show abstract

Experimental and clinical trial investigations of phyto-extracts, phyto-chemicals and phyto-formulations against oral lichen planus: A systematic review

Cited by 13 publications

References 150 publications

Combined Bioinformatics and Combinatorial Chemistry Tools to Locate Drug‐Able Anti‐TB Phytochemicals: A Cost‐Effective Platform for Natural Product‐Based Drug Discovery

Combined Bioinformatics and Combinatorial Chemistry Tools to Locate Drug‐Able Anti‐TB Phytochemicals: A Cost‐Effective Platform for Natural Product‐Based Drug Discovery

Apremilast Treatment of Cancer in Mice Tumorised with Breast Cancer: In Vivo Study

Biogenic Zinc Oxide Nanoparticles Attenuate Acute Lymphoblastic Leukemia Cell Proliferation through Oxidative Stress and DNA Damage

Contact Info

Product

Resources

About